Sean Secord, VP of Clinical Engagement at Nanostics Inc. comes to speak of the groundbreaking work that has been done to enhance the precision of PSA and MRI testing using machine learning under the new ClarityDX service. He talks about how US and Canada have handled PSA screenings the last decade, and how improvements with their AI analysis will make the PSA more effective than ever in accurately flagging prostate cancer. He talks about the growth in their platform and how do to its successful trials across the world is on the cusp of adoption among major national healthcare delivery.